Literature DB >> 18394873

Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension.

Zhu Junhui1, Wang Xingxiang, Fu Guosheng, Shang Yunpeng, Zhang Furong, Chen Junzhu.   

Abstract

BACKGROUND: Endothelial dysfunction plays a central and critical role in the initiation and development of idiopathic pulmonary arterial hypertension (IPAH), and a variety of evidence suggests that endothelial progenitor cells (EPCs) constitute one aspect of endothelium repair. In addition, transplantation of EPCs could attenuate pulmonary hypertension induced by monocrotaline in rats. However, it has not been examined and reported whether circulating EPCs from patients with IPAH are damaged.
METHODS: EPCs were isolated and cultured from patients with IPAH (n=20) and matched healthy volunteers (n=20). Circulating EPC numbers (enumerated as AC133+KDR+ cells) as well as migratory and adhesive activity were assessed. Blood levels of vascular endothelial growth factor (VEGF), homocysteine (Hcy), B-type natriuretic peptide (BNP), von Willebrand Factor (vWF) and interleukin-6 (IL-6) were also measured.
RESULTS: A significant decrease was observed in circulating EPC (AC133+KDR+ cells, 86.6+/-20.7cells/ml blood vs. 119.6+/-25.4cells/ml blood, P<0.001) numbers and the cell numbers expanded in vitro (47.2+/-14.5 vs. 70.7+/-15.2EPCs/x200 field; P<0.001) in patients with IPAH. EPCs from patients with IPAH were significantly impaired in their migratory capacity and ability to adhere to fibronectin. Blood levels of VEGF, Hcy, BNP, vWF and IL-6 were elevated in patients with IPAH. EPC numbers and activity were inversely related to Hcy, IL-6, BNP and vWF.
CONCLUSIONS: Our observations indicated that EPC numbers and functional capacity were impaired in patients with IPAH, which might not only give potential insight into the pathophysiological mechanisms but also might be useful for identifying suitable therapeutic targets in these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18394873     DOI: 10.1016/j.rmed.2007.12.030

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  44 in total

Review 1.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

2.  Bone Marrow-Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism.

Authors:  Nathaniel C Bloodworth; Cynthia R Clark; James D West; J Caleb Snider; Christa Gaskill; Sheila Shay; Christine Scott; Julie Bastarache; Santhi Gladson; Christy Moore; Reid D'Amico; Evan L Brittain; Harikrishna Tanjore; Timothy S Blackwell; Susan M Majka; W David Merryman
Journal:  Circ Res       Date:  2018-12-07       Impact factor: 17.367

3.  Aging is associated with a proapoptotic endothelial progenitor cell phenotype.

Authors:  Erich J Kushner; Owen J MacEneaney; Brian R Weil; Jared J Greiner; Brian L Stauffer; Christopher A DeSouza
Journal:  J Vasc Res       Date:  2011-05-31       Impact factor: 1.934

4.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

5.  Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension.

Authors:  Georg Hansmann; Brian D Plouffe; Adam Hatch; Alexander von Gise; Hannes Sallmon; Roham T Zamanian; Shashi K Murthy
Journal:  J Mol Med (Berl)       Date:  2011-07-07       Impact factor: 4.599

6.  Circulating endothelial and progenitor cells: Evidence from acute and long-term exercise effects.

Authors:  Matina Koutroumpi; Stavros Dimopoulos; Katherini Psarra; Theodoros Kyprianou; Serafim Nanas
Journal:  World J Cardiol       Date:  2012-12-26

7.  Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury.

Authors:  Sarah A Pendergrass; Everett Hayes; Giuseppina Farina; Raphael Lemaire; Harrison W Farber; Michael L Whitfield; Robert Lafyatis
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

8.  Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension.

Authors:  Mark Toshner; Robert Voswinckel; Mark Southwood; Rafia Al-Lamki; Luke S G Howard; Denis Marchesan; Jun Yang; Jay Suntharalingam; Elaine Soon; Andrew Exley; Susan Stewart; Markus Hecker; Zhenping Zhu; Ursula Gehling; Werner Seeger; Joanna Pepke-Zaba; Nicholas W Morrell
Journal:  Am J Respir Crit Care Med       Date:  2009-07-23       Impact factor: 21.405

Review 9.  ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.

Authors:  Colleen T Cole-Jeffrey; Meng Liu; Michael J Katovich; Mohan K Raizada; Vinayak Shenoy
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

10.  Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models.

Authors:  Vinayak Shenoy; Altin Gjymishka; Yagna P Jarajapu; Yanfei Qi; Aqeela Afzal; Katya Rigatto; Anderson J Ferreira; Rodrigo A Fraga-Silva; Patrick Kearns; Jane Yellowlees Douglas; Deepmala Agarwal; Kamal K Mubarak; Chastity Bradford; William R Kennedy; Joo Y Jun; Anandharajan Rathinasabapathy; Erin Bruce; Dipankar Gupta; Arturo J Cardounel; J Mocco; Jawaharlal M Patel; Joseph Francis; Maria B Grant; Michael J Katovich; Mohan K Raizada
Journal:  Am J Respir Crit Care Med       Date:  2013-01-31       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.